Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Biomedicines 2014, 2(3), 211-228; doi:10.3390/biomedicines2030211
Review

Toll-Like Receptor 9 Agonists for Cancer Therapy

1,2,* , 2
, 1
, 1
, 1
, 3
 and 2,3
Received: 17 April 2014; in revised form: 24 July 2014 / Accepted: 28 July 2014 / Published: 4 August 2014
(This article belongs to the Special Issue Gene Therapy Used in Cancer Treatment)
View Full-Text   |   Download PDF [1062 KB, uploaded 4 August 2014]   |   Browse Figure
Abstract: The immune system has acquired increasing importance as a key player in cancer maintenance and growth. Thus, modulating anti-tumor immune mediators has become an attractive strategy for cancer treatment. Toll-like receptors (TLRs) have gradually emerged as potential targets of newer immunotherapies. TLR-9 is preferentially expressed on endosome membranes of B-cells and plasmacytoid dendritic cells (pDC) and is known for its ability to stimulate specific immune reactions through the activation of inflammation-like innate responses. Several synthetic CpG oligonucleotides (ODNs) have been developed as TLR-9 agonists with the aim of enhancing cancer immune surveillance. In many preclinical models, CpG ODNs were found to suppress tumor growth and proliferation both in monotherapy and in addition to chemotherapies or target therapies. TLR-9 agonists have been also tested in several clinical trials in patients with solid tumors. These agents showed good tolerability and usually met activity endpoints in early phase trials. However, they have not yet been demonstrated to significantly impact survival, neither as single agent treatments, nor in combination with chemotherapies or cancer vaccines. Further investigations in larger prospective studies are required.
Keywords: TLR-9; CpG ODN; immune modulatory oligonucleotides; PF-3512676 TLR-9; CpG ODN; immune modulatory oligonucleotides; PF-3512676
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Melisi, D.; Frizziero, M.; Tamburrino, A.; Zanotto, M.; Carbone, C.; Piro, G.; Tortora, G. Toll-Like Receptor 9 Agonists for Cancer Therapy. Biomedicines 2014, 2, 211-228.

AMA Style

Melisi D, Frizziero M, Tamburrino A, Zanotto M, Carbone C, Piro G, Tortora G. Toll-Like Receptor 9 Agonists for Cancer Therapy. Biomedicines. 2014; 2(3):211-228.

Chicago/Turabian Style

Melisi, Davide; Frizziero, Melissa; Tamburrino, Anna; Zanotto, Marco; Carbone, Carmine; Piro, Geny; Tortora, Giampaolo. 2014. "Toll-Like Receptor 9 Agonists for Cancer Therapy." Biomedicines 2, no. 3: 211-228.

Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert